Are you Dr. Stocks?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
11937 Us Highway 271
Tyler, TX 75708Phone+1 903-877-7916Fax+1 903-877-5838
Summary
- Dr. James Stocks, MD is a pulmonologist in Tyler, Texas. He is currently licensed to practice medicine in Texas, Pennsylvania, and New Mexico. He is affiliated with UT Health North Campus Tyler and UT Health Tyler.
Education & Training
UPMC Medical EducationFellowship, Pulmonary Disease and Critical Care Medicine, 1982 - 1985- UPMC Medical EducationResidency, Internal Medicine, 1979 - 1982
University of Texas Southwestern Medical SchoolClass of 1979
Certifications & Licensure
TX State Medical License 1979 - 2026
NM State Medical License 2019 - 2024
PA State Medical License 2023 - 2024
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency Start of enrollment: 2010 Nov 01
- Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Start of enrollment: 2013 Nov 01
- Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 5 citationsA 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy.Jerome O. Cantor, Shuren Ma, Xingjian Liu, Michael Campos, C Strange
Respiratory Medicine. 2021-06-01 - 30 citationsAnalysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.Nishant Gupta, Hye-Seung Lee, Lisa R. Young, C Strange, Joel Moss
The European Respiratory Journal. 2019-04-01 - 5 citationsQuantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.Michael A. Tortorici, James A. Rogers, Oliver Vit, Martin Bexon, Robert A. Sandhaus
British Journal of Clinical Pharmacology. 2017-11-01
